Lidocaine Hydrochloride Supply (Pharmaceutical Vials)

The contract entails the supply and delivery of Lidocaine Hydrochloride in vial form, strictly adhering to FDA-approved National Drug Code specifications, to support medical readiness aboard a U.S. Navy vessel operating in the Pacific region. The pharmaceutical product is being procured under a subcontract arranged through the Defense Logistics Agency, a component of the Department of Defense, with the North American Industry Classification System code 424210 indicating wholesale distribution of pharmaceuticals and drug proprietaries. The delivery must be completed in accordance with military medical logistics protocols to ensure the medication is available for emergency or procedural use by medical personnel on the vessel. The solicitation was posted on June 26, 2026, and is managed under the contract number SPE2DX25D8022 with delivery order SPE2D926F6895, indicating a coordinated procurement effort within the DLA’s pharmaceutical supply chain. The place of performance is tied to a deployed naval asset, meaning the timing and conditions of delivery are critical to sustain operational effectiveness in a remote maritime environment. All vials must meet federal regulatory standards and be packaged and labeled to comply with military pharmaceutical handling requirements, ensuring safety, traceability, and immediate usability under field conditions.